Hypoxia, a potentially fatal shortage of oxygen in a body tissue, is a serious and potentially fatal medical condition. In Fueling Life, a new podcast from Diffusion Pharmaceuticals, we’ll discuss how and why hypoxia occurs, and explore how Diffusion Pharmaceuticals’ lead product candidate, Trans sodium crocetinate (TSC), represents a novel, targeted treatment opportunity to enhance the standard-of-care for conditions associated with hypoxia.
Oxygen is the fuel for life.
Its uptake and delivery within our body sustains us.
Whether we are on the move or at rest in sickness and in health.
The lack of oxygen in body tissue, a condition known as hypoxia, is a serious and potentially fatal complication of many challenging and difficult to treat medical conditions.
Diffusion Pharmaceuticals was founded with the vision to develop novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most.
In this podcast series, we’ll talk about how and why hypoxia can occur and how diffusion pharmaceuticals lead product candidate trans sodium crocetin, TSC, represents a novel targeted treatment opportunity for hypoxia.
You’ll meet the management team guiding diffusions development strategy at this pivotal moment in the company’s history, and we’ll delve into the team’s plans for developing TSC.
Fueling life, a podcast from Diffusion Pharmaceuticals.
Stay tuned for episode one, available wherever you get your podcasts.